<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">ACS Infect Dis</journal-id><journal-id journal-id-type="publisher-id">id</journal-id><journal-id journal-id-type="coden">aidcbc</journal-id><journal-title-group><journal-title>ACS Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2373-8227</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1021/acsinfecdis.0c00224</article-id><article-categories><subj-group><subject>Viewpoint</subject></subj-group></article-categories><title-group><article-title>COVID-19: Living through Another Pandemic</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Osman</surname><given-names>Essam Eldin A.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Toogood</surname><given-names>Peter L.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath3"><name><surname>Neamati</surname><given-names>Nouri</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><sup>&#x02020;</sup>Department of Medicinal Chemistry, College of Pharmacy and
<sup>&#x02021;</sup>Michigan Drug Discovery, Life Sciences Institute,
<institution>University of Michigan</institution>, Ann Arbor, Michigan 48109,
<country>United States</country></aff><aff id="aff2"><label>&#x000b6;</label>Department of Pharmaceutical Chemistry, Faculty of
Pharmacy, <institution>Cairo University</institution>, Cairo 11562,
<country>Egypt</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>neamati@med.umich.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>05</month><year>2020</year></pub-date><elocation-id>acsinfecdis.0c00224</elocation-id><history><date date-type="received"><day>20</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for unrestricted RESEARCH
re-use and analyses in any form or by any means with acknowledgement of the original
source. These permissions are granted for the duration of the World Health Organization
(WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract><p>Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus
disease-2019 (COVID-19), a globally pandemic infectious disease. Due to its high
virulence and the absence of immunity among the general population, SARS-CoV-2 has
quickly spread to all countries. This pandemic highlights the urgent unmet need to
expand and focus our research tools on what are considered &#x0201c;neglected infectious
diseases&#x0201d; and to prepare for future inevitable pandemics. This global emergency
has generated unprecedented momentum and scientific efforts around the globe unifying
scientists from academia, government and the pharmaceutical industry to accelerate the
discovery of vaccines and treatments. Herein, we shed light on the virus structure and
life cycle and the potential therapeutic targets in SARS-CoV-2 and briefly refer to both
active and passive immunization modalities, drug repurposing focused on speed to market,
and novel agents against specific viral targets as therapeutic interventions for
COVID-19.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>id0c00224</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>id0c00224</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">As first reported in December 2019, a novel coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), caused an outbreak of atypical pneumonia in Wuhan, China, that
has since spread globally.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The disease caused by this new virus has been
named coronavirus disease-2019 (COVID-19) and on March 11, 2020 was declared a global
pandemic by the World Health Organization (WHO).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Currently, there are
seven known human coronaviruses classified into two broad genera of alpha- and
beta-coronaviruses. The alpha-coronaviruses comprise HCoV-NL63 and HCoV-229E, while the
beta-coronaviruses comprise HCoV-OC43, HCoV-HKU1, SARS, Middle East Respiratory Syndrome
virus (MERS), and SARS-CoV-2.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The alpha-coronaviruses and HCoV-OC43 and
HCoV-HKU1 are among the causes of the common cold and have been circulating in human and
animal populations for many years.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> All these viruses originate from a
common ancestor and enter the human population through zoonotic transfer or species
jumping.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Although the first four known human coronaviruses originated
from birds, SARS, MERS, and SARS-CoV-2 appear, on the basis of gene sequence analysis, to
have originated from bats.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> However, in each case, these more recent
viruses appear to have been transmitted through an intermediate host such as a civet, a
small nocturnal mammal native to tropical Asia and Africa (SARS), a camel (MERS), or a
pangolin (SARS-CoV-2) after acquiring additional mutations.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Bats harbor
more strains of coronavirus than other mammals, estimated to range from 5000 to 10,000
distinct subtypes.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Therefore, additional epidemics are highly likely to
occur in the future due to the abundant number of coronaviruses present in the bat
population.</p><p>As of May 6th, 2020, more than 3.7 million cases of SARS-CoV-2 positive patients have been
reported worldwide with over 260,000 deaths, reflecting a &#x0223c;6.8% case fatality rate.
While the infection fatality rate is currently unknown, and likely to be lower than the
current case fatality rate, estimates suggest it is close to 1%, or approximately 10 times
the infection fatality rate of seasonal influenza (flu), which is fatal in only &#x0223c;0.1%
of infected patients.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In contrast to previous coronavirus epidemics
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Table S1</ext-link>), COVID-19 is indiscriminately wreaking havoc globally with no
apparent end in sight due to its high virulence and the absence of resistance among the
general population.</p><p>In general, all pandemics pass through three phases until they become endemic. The first
phase of &#x0201c;seeding&#x0201d; or slow spread is often not noticed early enough, leading
to dissemination of the disease before effective countermeasures can be initiated. During
the second phase, there is a rapid increase in cases until a peak occurs in the number of
infected individuals; parallel efforts to control and contain the virus can mitigate this
phase. In the third phase, the infection rate curve will start to decrease until the disease
becomes extinct or endemic. The kinetics of increase and decrease in the rate of infections
can vary significantly between populations depending on the use of preventive measures and
the availability of effective treatments. Previous coronavirus outbreaks and the current
pandemic highlight the urgent unmet medical need to expand and focus our research tools on
these long neglected infectious diseases and to prepare for future inevitable pandemics.
Herein, we briefly recap the current and potential future therapeutic interventions for
SARS-CoV-2 and highlight the recently published crystal structures of the SARS-CoV-2 main
protease and its inhibitors as novel agents against SARS-CoV-2.</p><sec id="sec2"><title>Virus Structure and Life Cycle</title><p>SARS-CoV-2 is an enveloped, nonsegmented single stranded, positive sense RNA virus. It has
one of the largest genomes among all RNA viruses, comprising approximately 30 kilobases (kb)
(NC_045512.2). SARS-CoV and SARS-CoV-2 belong to the same <italic>Coronaviridae</italic>
family that also includes the highly fatal Middle East Respiratory Syndrome virus (MERS)
that appeared in 2012.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> SARS-CoV-2 enters cells through the interaction
of its surface Spike protein with the host receptor, angiotensin-converting enzyme 2
(ACE2).<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Subsequent proteolytic cleavage by the host serine protease
TMPRSS2 or perhaps other proteases allows subsequent cell entry by endocytosis.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Upon membrane fusion and endocytosis, the viral nucleocapsid with its genome
payload is released into the cytoplasm of the infected cell. Following its release into the
host cell, the virus usurps portions of the endoplasmic reticulum to form numerous double
membrane vesicles.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> These vesicles are perfect sanctuaries to protect the
viral genome and allow an efficient replication process to occur through a macromolecule
complex called the replication&#x02013;transcription complex (RTC).<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The
viral genome is subsequently translated into viral polyproteins using the host cell protein
translation machinery, which are then cleaved into structural and nonstructural viral
proteins by two viral proteases, M<sup>pro</sup> and PL<sup>pro</sup>.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
This step is followed by the assembly of viral particles (virions) in the endoplasmic
reticulum/golgi compartment.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The packaged virions are then transported
to the cell surface, are released from the cells through exocytosis, and proceed to infect
other cells.</p></sec><sec id="sec3"><title>Clinical Course and Outcomes of COVID-19</title><p>SARS-CoV-2 likely binds to epithelial cells in the nasal cavity during the asymptomatic
state of the disease (initial 1&#x02013;2 days of infection) where there might be some local
propagation of the virus but with a limited innate immune response. Within the next few days
the infection starts in the upper airway and during this stage the infection can be detected
by nasal swabs or sputum as well as early markers of the innate immune response. About 80%
of infected patients show mild symptoms that are mostly restricted to the upper and
conducting airways.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> However, about 20% of infected patients will
progress to develop a lower respiratory tract infection leading to hypoxia, and lung damage.
These patients are liable to succumb to acute respiratory distress syndrome (ARDS), which is
frequently fatal. Patients with comorbidities such as cardiovascular disease, diabetes
mellitus, hypertension, chronic lung disease, cancer, chronic kidney disease, and obesity
(body mass index &#x02265;30) and ARDS are at increased risk of death.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
The available data indicate that the viral infection can produce an excessive immune
reaction known as cytokine release syndrome (CRS) or &#x0201c;cytokine storm&#x0201d;
associated with elevated levels of interleukin-6 (IL-6).<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Laboratory
findings associated with worse clinical outcomes include lymphopenia, and elevations in
liver enzymes, lactate dehydrogenase (LDH), inflammatory markers (e.g., C-reactive protein
[CRP], ferritin), <sc>d</sc>-dimer, prothrombin time (PT), troponin and creatine
phosphokinase (CPK), and acute kidney injury.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Chest CT scans in
patients with COVID-19 commonly show ground-glass opacification, consistent with viral
pneumonia with abnormalities more likely to be bilateral with a peripheral distribution
involving the lower lobes.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> While SARS-CoV-2 entry is dependent on ACE2
in lung cells,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> ACE2 expression is not exclusive to the lungs, and higher
relative ACE2 expression is observed in heart, kidney, GIT, and testes (Gene ID: 59272). The
organ- and cell-specific expression of ACE2 suggests that it may play a role in the
regulation of cardiovascular and renal function as well as fertility. Surprisingly, the 2003
SARS-CoV infection was shown to downregulate the expression of ACE2 in lung tissue reducing
transmissibility but increasing virulence.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> ACE2, a component of the
renin-angiotensin system (RAS), catalyzes the cleavage of angiotensin I into angiotensin
1&#x02013;9 and angiotensin II into the vasodilator angiotensin 1&#x02013;7.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The balance between angiotensin II and angiotensin (1&#x02013;7) is critical
since angiotensin II elicits vasoconstriction via the angiotensin AT1 receptor, whereas
angiotensin (1&#x02013;7) exerts a vasodilatory effect mediated by AT2 with multiple
beneficial effects on the cardiovascular and respiratory system.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> While
ACE2 appears to be involved in the hypertension and respiratory manifestations of severely
ill patients, the benefits and merits of ACE inhibitors (ACEI) or angiotensin receptor 1
blockers (ARBs) in the SARS-CoV-2 patient is still controversial.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The
priming of the S viral protein by TMPRSS2 is crucial for viral entry where TMPRSS2
expression is very high in the lungs, kidneys, and prostate tissue (Gene ID: 7113).<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> TMPRSS2 is predominantly expressed in the luminal cells of the prostate
epithelium, where its expression is regulated positively by androgens and negatively
regulated by estrogens. The hormonal regulation of TMPRSS2 has been suggested to be linked
to the fact that men are at higher risk than women to become seriously ill with
COVID-19.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> TMPRSS2 knockout in mice is not lethal. In contrast, humans
are intolerant to the loss of function of ACE2.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Concerns about the
effect of ACEI and AT receptor blockers in COVID-19 patients are actively being investigated
in the clinic, with the most recent reports offering encouragement that they may have a
beneficial effect.</p></sec><sec id="sec4"><title>Potential Drug Targets</title><p>SARS-CoV-2 viral RNA encodes several proteins that are potentially druggable targets (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Table S2</ext-link>), including four structural proteins: the Spike (S), Envelope (E),
Membrane (M), and Nucleocapsid (N).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The 1273 amino acid, 141 kDa, Spike
protein is heavily N-glycosylated and is a major inducer of host immune responses. The 222
amino acid M protein has three transmembrane domains and is the most abundant structural
protein in the virion. The 75 amino acid E protein is important for assembly and release of
the virus. The 419 amino acid nucleocapsid protein forms a protective protein shell around
the virus genetic material and is encased in a lipid envelope that is usurped from the host
cell. Matrix protein connects the membrane to the nucleocapsid protein. There are also 16
nonstructural proteins (nsp1&#x02013;16)<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> including several for which
there are X-ray crystallography-derived structural data: RNA dependent RNA polymerase
(nsp12, RdRp), a papain-like protease (nsp3, PLpro), the main protease (nsp5,
3CL<sup>pro</sup>, or M<sup>pro</sup>), and exonuclease/N7-methyltransferase (nsp14,
ExoN). RdRp catalyzes synthesis of the full length negative-strand RNA template used by RdRp
to make more viral genomic RNA. The SARS-CoV-2 genome also contains a number of open reading
frames (ORFs): namely, ORF 1a proposed to encode nsp1 to nsp11; ORF1b, is proposed to encode
nsp12 to nsp16, essential for viral replication, and ORFs 3a, 3b, 6, 7a, 7b, 8, 9a, 9b, and
10, which encode for accessory proteins<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Table S2</ext-link>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>SARS-CoV-2 encoded proteins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00224_0001" id="gr1" position="float"/></fig></sec><sec id="sec5"><title>Treating Viral Infection</title><sec id="sec5.1"><title>Immunization against SARS-CoV-2</title><p>The development of a manufacturable, safe, and effective vaccine may take 12&#x02013;18
months. Several phase I clinical trials are currently recruiting participants to test the
safety, reactogenicity, and immunogenicity of several investigational SARS-CoV-2 vaccines
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Tables S3 and S4</ext-link>). An mRNA vaccine based on the Spike protein began human
clinical trials within a record 63 days from first publication of the SARS-CoV-2 sequence
(NCT04283461). It has been suggested that the mutation rate for SARS-CoV-2 is expected to
be low, raising hope that a successful vaccine will provide life-long immunity.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Hyperimmune globulin isolated from the sera of convalescent patients
having high titers of antibodies against SARS-CoV-2 or even their whole blood may provide
instant &#x0201c;passive&#x0201d; short-lived immunity mainly via viral neutralization.
Antibody dependent therapy, for example targeting the Spike protein might represent the
most efficient, near-term therapeutic intervention if regulatory and safety requirements
can be addressed. With over 1.3 million positive cases of COVID-19 in the US based solely
on the results of RNA molecular tests, large-scale antibody testing should be expedited to
identify individuals who have been exposed to the virus but were never officially
confirmed to have COVID-19. An understanding what levels of antibody confer immunity
postinfection could be used to determine who may be less likely to transmit the virus and
thus may be able to go back safely to work.</p></sec><sec id="sec5.2"><title>Drug Repurposing</title><p>Developing highly selective SARS-CoV-2 specific new drugs will take many years.
Alternatively, repurposing of existing, approved drugs can present a more rapid strategy
to identifying drugs effective in treating COVID-19 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Tables S3 and S4 and Figure S1</ext-link>).<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Repurposing of drugs
that would block SARS-CoV-2 entry and/or replication are urgently needed to mitigate the
symptomatic burden of the disease. Unfortunately, the HIV protease inhibitors
ritonavir/liponavir failed to show efficacy in SARS-CoV-2 infected patients.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Hydroxychloroquine, which may act by increasing the pH within lysosomes,
was granted FDA authorization for use in emergency cases. Several antiviral agents are
being tested such as the RdRp inhibitor remdesivir and the approved anti-influenza drug
faviprivir.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Remdesivir was previously tested in humans with Ebola
virus disease and also in animal models of MERS and SARS-CoV.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> At
least six clinical trials are evaluating remdesivir in SARS-CoV-2 patients. Other drugs
that might inhibit RdRp include the broad-spectrum antiviral drug ribavirin. RdRp
conservation among RNA virus families makes it an exciting target for the discovery of
newer agents. The Spike protein, ACE2, and TMPRSS2 may also represent interesting
therapeutic targets for current drug repurposing efforts. Camostat mesylate, approved in
Japan for treatment of pancreatic inflammation, has been shown to block TMPRSS2
activity.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Arbidol, which is hypothesized to block Spike/ACE2
binding, is being investigated clinically, and a clinical trial was recently launched to
study the effect of thiazide, thiazide-like diuretics, calcium channel blockers, ACE
inhibitors, and angiotensin receptor blockers in COVID-19 (NCT04330300). The availability
of soluble recombinant hACE2 encouraged its testing in two clinical trials; although one
was terminated (NCT04287686) the other is currently active (NCT04335136). Monoclonal
antibodies, especially for interleukin-6 (IL-6) or its receptor, are also being considered
for the control of SARS-CoV-2 associated respiratory exacerbations.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
Interestingly, several Janus Kinase (JAK) inhibitors such as baricitinib and ruxolitinib
are currently being evaluated given their involvement in interleukin signaling pathways.
Another currently recruiting clinical trial is testing quinolone, macrolide, and
&#x003b2;-lactam antibiotics against COVID-19 (NCT02735707). Multiple groups have tested FDA
approved drugs in various <italic>in vitro</italic> assays as well as in computational
screens. Many of these drugs show inhibitory activities, although not always at a
concentration that may be safely achieved in patients.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Controlled
clinical trials of these agents are mandatory to assess their efficacy and safety without
creating false positive hope or depleting the supplies of drugs needed to treat the
diseases for which they were initially approved.</p></sec><sec id="sec5.3"><title>Novel Agents</title><p>M<sup>pro</sup> and PL<sup>pro</sup> are cysteine proteases responsible for the cleavage
of viral polypeptides into functional proteins for virus replication and packaging within
host cells.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> These enzymes represent the best characterized drug
targets among coronaviruses and are currently the focus of attention among scientists
seeking novel coronavirus small molecule therapeutics.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
M<sup>pro</sup> is shared by all coronavirus genera and has similarity to the
3C<sup>pro</sup> of the <italic>Enterovirus</italic> genus in the picornavirus
family.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> M<sup>pro</sup> contains a Cys&#x000b7;&#x000b7;&#x000b7;His
catalytic dyad with an additional &#x003b1;-helical domain involved in the dimerization of
the protease, which is essential for its catalytic activity.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> The
enteroviral 3C<sup>pro</sup> functions as a monomer featuring a classical
Cys&#x000b7;&#x000b7;&#x000b7;His&#x000b7;&#x000b7;&#x000b7;Glu/Asp catalytic triad.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup>
Yet, they share the almost absolute requirement for Gln in the P1 position of the
substrate and space for only small residues such as Gly, Ala, or Ser in the P1&#x02032;
position. Since no human proteases with a similar cleavage specificity are known, it may
be possible to identify highly selective M<sup>pro</sup>/3C<sup>pro</sup> inhibitors,
which display minimal inhibition of host proteases.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> The 3-D
structures of unliganded SARS-CoV-2 M<sup>pro</sup> and of its complex with a
peptidomimetic &#x003b1;-ketoamide inhibitor (<bold>11r</bold>) have been solved<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> and were used to support the design of an optimized derivative
(<bold>13b</bold>) through docking studies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Figure S2</ext-link>). &#x003b1;-Ketoamides can interact with the catalytic center of
M<sup>pro</sup> through two hydrogen bonding interactions rather than only one as with
other warheads such as aldehydes or Michael acceptors.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Nucleophilic
attack of the &#x003b1;-keto group by the catalytic Cys residue results in reversible
formation of a thiohemiketal. These &#x003b1;-ketoamides feature a 5-membered rigid
&#x003b3;-lactam as a mimic of the P1 residue, glutamine, required for M<sup>pro</sup>
specificity, with the advantage of reducing the loss of entropy upon binding.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Follow up optimization efforts guided by docking to the SARS-CoV-2
M<sup>pro</sup> co-crystal structure with <bold>11r</bold>, included incorporation of
the P3-P2 amide bond into a pyridone ring as in <bold>13a</bold>. The resulting half-life
of <bold>13a</bold> in plasma was enhanced by 3 fold relative to <bold>11r</bold>,
<italic>in vitro</italic> kinetic plasma solubility improved by a factor of &#x0223c;19
and thermodynamic solubility by a factor of &#x0223c;13. <bold>13a</bold> inhibited
purified recombinant SARS-CoV-2 M<sup>pro</sup>, SARS-CoV M<sup>pro</sup>, and MERS-CoV
M<sup>pro</sup> in the submicromolar range.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Modification of the
P1&#x02032; and P3 moieties of <bold>13a</bold> afforded an optimized derivative
<bold>13b</bold> which was crystallized with SARS-CoV-2 M<sup>pro</sup> (PDB: 6Y2G and 6Y2F). Both <bold>13a</bold> and <bold>13b</bold> displayed good
stability in mouse and human microsomes. <bold>13b</bold> (3 mg/kg) showed longer
<italic>t</italic><sub>1/2</sub>, <italic>t</italic><sub>max</sub>, and residence time
compared to <bold>13a</bold> (20 mg/kg) in CD-1 mice. Both compounds showed lung tropism
which is thought to be beneficial. While the development of these ketoamides into clinical
candidates requires additional safety studies, the availability of their crystal
structures is of great importance in facilitating the discovery and development of other
M<sup>pro</sup> inhibitors. One of the suggested agents for testing is the previously
reported Rhinovirus and SARS-CoV M<sup>pro</sup> inhibitor clinical candidate rupintrivir
(AG-7088) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Figure S2</ext-link>). In addition, other groups recently reported M<sup>pro</sup>
crystal structures with inhibitors such as the peptidomimetic Michael acceptor
<bold>N3</bold> (PDB: 6LU7) and
the reversible inhibitor <bold>X77</bold> (PDB: 6W63) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">Figure S2</ext-link>).<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> A large array of M<sup>pro</sup> crystal
structures with multiple covalent and noncovalent fragments were solved through an
exceptionally large screen with vast opportunities for fragment growing and merging. The
cryo EM structure of SARS-CoV-2 RdRp was recently solved, showing nearly an identical
sequence to its SARS-CoV homologue.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> RdRp should be another high
priority target for therapeutic intervention given that lead inhibitors such as remdesivir
already exist.</p></sec></sec><sec id="sec6"><title>Conclusions</title><p>Since 2003, the three pandemics caused by SARS, MERS, and SARS-CoV-2 are believed to have
initiated as a result of bat coronaviruses crossing the species barrier. Therefore, other
epidemics are likely to occur in the future due to the effectively unlimited supply of
coronaviruses present in the bat population. Equally concerning is the fact that RNA viruses
lack a genomic proof-reading mechanism and therefore are prone to mutation, raising the
specter that once a new coronavirus begins circulating in the human population it will be
extremely difficult to eliminate. Finally, for a drug to be most effective, it must reach
its site of action (e.g., lung tissues) in sufficient quantity to clear the virus. With
nearly three million reported cases, &#x0003e;260,000 deaths, millions out of work, and billions
of dollars in lost revenue, it appears that SARS-CoV-2 has altered daily life for a
sustained period of time. This cascading effect has generated unprecedented momentum and
scientific effort around the globe to fight this virus. Success will require creative
thinking, new technologies, innovative approaches, particularly focused on speed to market,
and combinations of different modalities to effectively combat not just the current foe but
also future coronaviruses. We remain hopeful that we will be more prepared for the emergence
of a potential &#x0201c;SARS-CoV-3&#x0201d;.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00224</ext-link>.<list id="silist" list-type="simple"><list-item><p>Tables showing viral outbreaks since year 2000, different
targets expressed in SARS-CoV-2 proteome, unique therapeutic interventions in
recruiting and nonrecruiting clinical studies for COVID-19, and structures of select
approved or investigational drugs tested for drug repurposing against SARS-CoV-2;
structures of the novel inhibitors obtained from the PDB for SARS-CoV-2
M<sup>pro</sup> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.0c00224/suppl_file/id0c00224_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="id0c00224_si_001.pdf"><caption><p>id0c00224_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="COI-statement" id="NOTES-d7e522-autogenerated"><p>The authors declare no competing financial interest.</p></notes><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Wu</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>B.</given-names></name>; <name><surname>Chen</surname><given-names>Y. M.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Song</surname><given-names>Z. G.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Tao</surname><given-names>Z. W.</given-names></name>; <name><surname>Tian</surname><given-names>J. H.</given-names></name>; <name><surname>Pei</surname><given-names>Y. Y.</given-names></name>; <name><surname>Yuan</surname><given-names>M. L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y. L.</given-names></name>; <name><surname>Dai</surname><given-names>F. H.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Q. M.</given-names></name>; <name><surname>Zheng</surname><given-names>J. J.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Holmes</surname><given-names>E. C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y. Z.</given-names></name> (<year>2020</year>) <article-title>A new coronavirus associated with human respiratory disease in
China</article-title>. <source>Nature</source>
<volume>579</volume> (<issue>7798</issue>), <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id>.<pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Chan</surname><given-names>J. F.</given-names></name>; <name><surname>Kok</surname><given-names>K. H.</given-names></name>; <name><surname>Zhu</surname><given-names>Z.</given-names></name>; <name><surname>Chu</surname><given-names>H.</given-names></name>; <name><surname>To</surname><given-names>K. K.</given-names></name>; <name><surname>Yuan</surname><given-names>S.</given-names></name>; <name><surname>Yuen</surname><given-names>K. Y.</given-names></name> (<year>2020</year>) <article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus
isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>. <source>Emerging Microbes Infect.</source>
<volume>9</volume> (<issue>1</issue>), <fpage>221</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Parrish</surname><given-names>C. R.</given-names></name>; <name><surname>Holmes</surname><given-names>E. C.</given-names></name>; <name><surname>Morens</surname><given-names>D. M.</given-names></name>; <name><surname>Park</surname><given-names>E. C.</given-names></name>; <name><surname>Burke</surname><given-names>D. S.</given-names></name>; <name><surname>Calisher</surname><given-names>C. H.</given-names></name>; <name><surname>Laughlin</surname><given-names>C. A.</given-names></name>; <name><surname>Saif</surname><given-names>L. J.</given-names></name>; <name><surname>Daszak</surname><given-names>P.</given-names></name> (<year>2008</year>) <article-title>Cross-species virus transmission and the emergence of new epidemic
diseases</article-title>. <source>Microbiol. Mol. Biol. Rev.</source>
<volume>72</volume> (<issue>3</issue>), <fpage>457</fpage>&#x02013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00004-08</pub-id>.<pub-id pub-id-type="pmid">18772285</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Hu</surname><given-names>B.</given-names></name>; <name><surname>Ge</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>L. F.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name> (<year>2015</year>) <article-title>Bat origin of human coronaviruses</article-title>. <source>Virol. J.</source>
<volume>12</volume>, <fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0422-1</pub-id>.<pub-id pub-id-type="pmid">26689940</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Yu</surname><given-names>M.</given-names></name>; <name><surname>Ren</surname><given-names>W.</given-names></name>; <name><surname>Smith</surname><given-names>C.</given-names></name>; <name><surname>Epstein</surname><given-names>J. H.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Crameri</surname><given-names>G.</given-names></name>; <name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>McEachern</surname><given-names>J.</given-names></name>; <name><surname>Field</surname><given-names>H.</given-names></name>; <name><surname>Daszak</surname><given-names>P.</given-names></name>; <name><surname>Eaton</surname><given-names>B. T.</given-names></name>; <name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>L. F.</given-names></name> (<year>2005</year>) <article-title>Bats are natural reservoirs of SARS-like coronaviruses</article-title>. <source>Science</source>
<volume>310</volume> (<issue>5748</issue>), <fpage>676</fpage>&#x02013;<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1126/science.1118391</pub-id>.<pub-id pub-id-type="pmid">16195424</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Ejima</surname><given-names>K.</given-names></name>; <name><surname>Omori</surname><given-names>R.</given-names></name>; <name><surname>Cowling</surname><given-names>B. J.</given-names></name>; <name><surname>Aihara</surname><given-names>K.</given-names></name>; <name><surname>Nishiura</surname><given-names>H.</given-names></name> (<year>2012</year>) <article-title>The time required to estimate the case fatality ratio of influenza using
only the tip of an iceberg: joint estimation of the virulence and the transmission
potential</article-title>. <source>Comput. Math Methods Med.</source>
<volume>2012</volume>, <fpage>978901</fpage><pub-id pub-id-type="doi">10.1155/2012/978901</pub-id>.<pub-id pub-id-type="pmid">22649483</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"> (<year>2020</year>) <article-title>The species severe acute respiratory syndrome-related coronavirus:
classifying 2019-nCoV and naming it SARS-CoV-2</article-title>. <source>Nat. Microbiol.</source>
<volume>5</volume> (<issue>4</issue>), <fpage>536</fpage>&#x02013;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id>.<pub-id pub-id-type="pmid">32123347</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Hoffmann</surname><given-names>M.</given-names></name>; <name><surname>Kleine-Weber</surname><given-names>H.</given-names></name>; <name><surname>Schroeder</surname><given-names>S.</given-names></name>; <name><surname>Kruger</surname><given-names>N.</given-names></name>; <name><surname>Herrler</surname><given-names>T.</given-names></name>; <name><surname>Erichsen</surname><given-names>S.</given-names></name>; <name><surname>Schiergens</surname><given-names>T. S.</given-names></name>; <name><surname>Herrler</surname><given-names>G.</given-names></name>; <name><surname>Wu</surname><given-names>N. H.</given-names></name>; <name><surname>Nitsche</surname><given-names>A.</given-names></name>; <name><surname>Muller</surname><given-names>M. A.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>Pohlmann</surname><given-names>S.</given-names></name> (<year>2020</year>) <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
clinically proven protease inhibitor</article-title>. <source>Cell</source>
<volume>181</volume> (<issue>2</issue>), <fpage>271</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Knoops</surname><given-names>K.</given-names></name>; <name><surname>Kikkert</surname><given-names>M.</given-names></name>; <name><surname>Worm</surname><given-names>S. H.</given-names></name>; <name><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name>; <name><surname>van der Meer</surname><given-names>Y.</given-names></name>; <name><surname>Koster</surname><given-names>A. J.</given-names></name>; <name><surname>Mommaas</surname><given-names>A. M.</given-names></name>; <name><surname>Snijder</surname><given-names>E. J.</given-names></name> (<year>2008</year>) <article-title>SARS-coronavirus replication is supported by a reticulovesicular network of
modified endoplasmic reticulum</article-title>. <source>PLoS Biol.</source>
<volume>6</volume> (<issue>9</issue>), <elocation-id>e226</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0060226</pub-id>.<pub-id pub-id-type="pmid">18798692</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Hagemeijer</surname><given-names>M. C.</given-names></name>; <name><surname>Verheije</surname><given-names>M. H.</given-names></name>; <name><surname>Ulasli</surname><given-names>M.</given-names></name>; <name><surname>Shaltiel</surname><given-names>I. A.</given-names></name>; <name><surname>de Vries</surname><given-names>L. A.</given-names></name>; <name><surname>Reggiori</surname><given-names>F.</given-names></name>; <name><surname>Rottier</surname><given-names>P. J.</given-names></name>; <name><surname>de Haan</surname><given-names>C. A.</given-names></name> (<year>2010</year>) <article-title>Dynamics of coronavirus replication-transcription complexes</article-title>. <source>J. Virol.</source>
<volume>84</volume> (<issue>4</issue>), <fpage>2134</fpage>&#x02013;<lpage>2149</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01716-09</pub-id>.<pub-id pub-id-type="pmid">20007278</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>Q.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Garner</surname><given-names>L. V.</given-names></name>; <name><surname>Watkins</surname><given-names>S. P.</given-names></name>; <name><surname>Carter</surname><given-names>L. J.</given-names></name>; <name><surname>Smoot</surname><given-names>J.</given-names></name>; <name><surname>Gregg</surname><given-names>A. C.</given-names></name>; <name><surname>Daniels</surname><given-names>A. D.</given-names></name>; <name><surname>Jervey</surname><given-names>S.</given-names></name>; <name><surname>Albaiu</surname><given-names>D.</given-names></name> (<year>2020</year>) <article-title>Research and development on therapeutic agents and vaccines for COVID-19
and related human coronavirus diseases</article-title>. <source>ACS Cent. Sci.</source>
<volume>6</volume> (<issue>3</issue>), <fpage>315</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id>.<pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>de Haan</surname><given-names>C. A.</given-names></name>; <name><surname>Kuo</surname><given-names>L.</given-names></name>; <name><surname>Masters</surname><given-names>P. S.</given-names></name>; <name><surname>Vennema</surname><given-names>H.</given-names></name>; <name><surname>Rottier</surname><given-names>P. J.</given-names></name> (<year>1998</year>) <article-title>Coronavirus particle assembly: primary structure requirements of the
membrane protein</article-title>. <source>J. Virol.</source>
<volume>72</volume> (<issue>8</issue>), <fpage>6838</fpage>&#x02013;<lpage>6850</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.72.8.6838-6850.1998</pub-id>.<pub-id pub-id-type="pmid">9658133</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>McGoogan</surname><given-names>J. M. J. J.</given-names></name> (<year>2020</year>) <article-title>Characteristics of and important lessons from the coronavirus disease 2019
(COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese
Center for Disease Control and Prevention</article-title>. <source>JAMA</source>
<volume>323</volume> (<issue>13</issue>), <fpage>1239</fpage>&#x02013;<lpage>1242</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Yu</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Shu</surname><given-names>H.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Fang</surname><given-names>M.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Pan</surname><given-names>S.</given-names></name>; <name><surname>Zou</surname><given-names>X.</given-names></name>; <name><surname>Yuan</surname><given-names>S.</given-names></name>; <name><surname>Shang</surname><given-names>Y.</given-names></name> (<year>2020</year>) <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2
pneumonia in Wuhan, China: a single-centered, retrospective, observational
study</article-title>. <source>Lancet Respir. Med.</source>
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Du</surname><given-names>R.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Xiang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Song</surname><given-names>B.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Guan</surname><given-names>L.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Tu</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Cao</surname><given-names>B.</given-names></name> (<year>2020</year>) <article-title>Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>
<volume>395</volume> (<issue>10229</issue>), <fpage>1054</fpage>&#x02013;<lpage>1062</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Jiang</surname><given-names>F.</given-names></name>; <name><surname>Deng</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Cheung</surname><given-names>C. W.</given-names></name>; <name><surname>Xia</surname><given-names>Z.</given-names></name> (<year>2020</year>) <article-title>Review of the clinical characteristics of coronavirus disease 2019
(COVID-19)</article-title>. <source>J. Gen Intern Med.</source>
<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-020-05762-w</pub-id>.<pub-id pub-id-type="pmid">31625040</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Kuba</surname><given-names>K.</given-names></name>; <name><surname>Imai</surname><given-names>Y.</given-names></name>; <name><surname>Rao</surname><given-names>S.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>F.</given-names></name>; <name><surname>Guan</surname><given-names>B.</given-names></name>; <name><surname>Huan</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Deng</surname><given-names>W.</given-names></name>; <name><surname>Bao</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Chappell</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>D.</given-names></name>; <name><surname>Leibbrandt</surname><given-names>A.</given-names></name>; <name><surname>Wada</surname><given-names>T.</given-names></name>; <name><surname>Slutsky</surname><given-names>A. S.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>; <name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Jiang</surname><given-names>C.</given-names></name>; <name><surname>Penninger</surname><given-names>J. M.</given-names></name> (<year>2005</year>) <article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
coronavirus-induced lung injury</article-title>. <source>Nat. Med.</source>
<volume>11</volume> (<issue>8</issue>), <fpage>875</fpage>&#x02013;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1038/nm1267</pub-id>.<pub-id pub-id-type="pmid">16007097</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Penninger</surname><given-names>J. M.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhong</surname><given-names>N.</given-names></name>; <name><surname>Slutsky</surname><given-names>A. S.</given-names></name> (<year>2020</year>) <article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular
mechanisms and potential therapeutic target</article-title>. <source>Intensive Care Med.</source>
<volume>46</volume> (<issue>4</issue>), <fpage>586</fpage>&#x02013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id>.<pub-id pub-id-type="pmid">32125455</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="book" id="cit19"><person-group><name><surname>Wang</surname><given-names>X.</given-names></name>, <name><surname>Dhindsa</surname><given-names>R.</given-names></name>, <name><surname>Povysil</surname><given-names>G.</given-names></name>, <name><surname>Zoghbi</surname><given-names>A.</given-names></name>, <name><surname>Motelow</surname><given-names>J.</given-names></name>, <name><surname>Hostyk</surname><given-names>J.</given-names></name>, and <name><surname>Goldstein</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>)
<article-title>Transcriptional inhibition of host viral entry proteins as a therapeutic
strategy for SARS-CoV-2</article-title>. <source>Preprints</source>, 2020030360,
<pub-id pub-id-type="doi">10.20944/preprints202003.0360.v1</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Andersen</surname><given-names>K. G.</given-names></name>; <name><surname>Rambaut</surname><given-names>A.</given-names></name>; <name><surname>Lipkin</surname><given-names>W. I.</given-names></name>; <name><surname>Holmes</surname><given-names>E. C.</given-names></name>; <name><surname>Garry</surname><given-names>R. F.</given-names></name> (<year>2020</year>) <article-title>The proximal origin of SARS-CoV-2</article-title>. <source>Nat. Med.</source>
<volume>26</volume> (<issue>4</issue>), <fpage>450</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id>.<pub-id pub-id-type="pmid">32284615</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Cao</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wen</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Fan</surname><given-names>G.</given-names></name>; <name><surname>Ruan</surname><given-names>L.</given-names></name>; <name><surname>Song</surname><given-names>B.</given-names></name>; <name><surname>Cai</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>N.</given-names></name>; <name><surname>Xiang</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Bai</surname><given-names>T.</given-names></name>; <name><surname>Xie</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Huang</surname><given-names>H.</given-names></name>; <name><surname>Tu</surname><given-names>S.</given-names></name>; <name><surname>Gong</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Dong</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Shang</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Dong</surname><given-names>X.</given-names></name>; <name><surname>Qu</surname><given-names>Z.</given-names></name>; <name><surname>Lu</surname><given-names>S.</given-names></name>; <name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Ruan</surname><given-names>S.</given-names></name>; <name><surname>Luo</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Peng</surname><given-names>L.</given-names></name>; <name><surname>Cheng</surname><given-names>F.</given-names></name>; <name><surname>Pan</surname><given-names>L.</given-names></name>; <name><surname>Zou</surname><given-names>J.</given-names></name>; <name><surname>Jia</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Ge</surname><given-names>Q.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Zhan</surname><given-names>H.</given-names></name>; <name><surname>Qiu</surname><given-names>F.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Jaki</surname><given-names>T.</given-names></name>; <name><surname>Hayden</surname><given-names>F. G.</given-names></name>; <name><surname>Horby</surname><given-names>P. W.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name> (<year>2020</year>) <article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe
COVID-19</article-title>. <source>N. Engl. J. Med.</source>
<pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Kawase</surname><given-names>M.</given-names></name>; <name><surname>Shirato</surname><given-names>K.</given-names></name>; <name><surname>van der Hoek</surname><given-names>L.</given-names></name>; <name><surname>Taguchi</surname><given-names>F.</given-names></name>; <name><surname>Matsuyama</surname><given-names>S.</given-names></name> (<year>2012</year>) <article-title>Simultaneous treatment of human bronchial epithelial cells with serine and
cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus
entry</article-title>. <source>J. Virol</source>
<volume>86</volume> (<issue>12</issue>), <fpage>6537</fpage>&#x02013;<lpage>6545</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00094-12</pub-id>.<pub-id pub-id-type="pmid">22496216</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="book" id="cit23"><person-group><name><surname>Jeon</surname><given-names>S.</given-names></name>, <name><surname>Ko</surname><given-names>M.</given-names></name>, <name><surname>Lee</surname><given-names>J.</given-names></name>, <name><surname>Choi</surname><given-names>I.</given-names></name>, <name><surname>Byun</surname><given-names>S.
Y.</given-names></name>, <name><surname>Park</surname><given-names>S.</given-names></name>,
<name><surname>Shum</surname><given-names>D.</given-names></name>, and
<name><surname>Kim</surname><given-names>S.</given-names></name></person-group>
(<year>2020</year>) <article-title>Identification of antiviral drug candidates against
SARS-CoV-2 from FDA-approved drugs</article-title>. <source>bioRxiv</source>,
<pub-id pub-id-type="doi">10.1101/2020.03.20.999730</pub-id>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Lin</surname><given-names>D.</given-names></name>; <name><surname>Kusov</surname><given-names>Y.</given-names></name>; <name><surname>Nian</surname><given-names>Y.</given-names></name>; <name><surname>Ma</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>von Brunn</surname><given-names>A.</given-names></name>; <name><surname>Leyssen</surname><given-names>P.</given-names></name>; <name><surname>Lanko</surname><given-names>K.</given-names></name>; <name><surname>Neyts</surname><given-names>J.</given-names></name>; <name><surname>de Wilde</surname><given-names>A.</given-names></name>; <name><surname>Snijder</surname><given-names>E. J.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Hilgenfeld</surname><given-names>R.</given-names></name> (<year>2020</year>) <article-title>Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and
enterovirus replication: structure-based design, synthesis, and activity
assessment</article-title>. <source>J. Med. Chem.</source>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01828</pub-id>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name> (<year>2014</year>) <article-title>From SARS to MERS: crystallographic studies on coronaviral proteases enable
antiviral drug design</article-title>. <source>FEBS J.</source>
<volume>281</volume> (<issue>18</issue>), <fpage>4085</fpage>&#x02013;<lpage>4096</lpage>. <pub-id pub-id-type="doi">10.1111/febs.12936</pub-id>.<pub-id pub-id-type="pmid">25039866</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Lin</surname><given-names>D.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Curth</surname><given-names>U.</given-names></name>; <name><surname>Drosten</surname><given-names>C.</given-names></name>; <name><surname>Sauerhering</surname><given-names>L.</given-names></name>; <name><surname>Becker</surname><given-names>S.</given-names></name>; <name><surname>Rox</surname><given-names>K.</given-names></name>; <name><surname>Hilgenfeld</surname><given-names>R.</given-names></name> (<year>2020</year>) <article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design
of improved alpha-ketoamide inhibitors</article-title>. <source>Science</source>
<fpage>eabb3405</fpage><pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><person-group person-group-type="allauthors"><name><surname>Jin</surname><given-names>Z.</given-names></name>,
<name><surname>Du</surname><given-names>X.</given-names></name>,
<name><surname>Xu</surname><given-names>Y.</given-names></name>,
<name><surname>Deng</surname><given-names>Y.</given-names></name>,
<name><surname>Liu</surname><given-names>M.</given-names></name>,
<name><surname>Zhao</surname><given-names>Y.</given-names></name>,
<name><surname>Zhang</surname><given-names>B.</given-names></name>,
<name><surname>Li</surname><given-names>X.</given-names></name>,
<name><surname>Zhang</surname><given-names>L.</given-names></name>,
<name><surname>Peng</surname><given-names>C.</given-names></name>,
<name><surname>Duan</surname><given-names>Y.</given-names></name>,
<name><surname>Yu</surname><given-names>J.</given-names></name>,
<name><surname>Wang</surname><given-names>L.</given-names></name>,
<name><surname>Yang</surname><given-names>K.</given-names></name>,
<name><surname>Liu</surname><given-names>F.</given-names></name>,
<name><surname>Jiang</surname><given-names>R.</given-names></name>,
<name><surname>Yang</surname><given-names>X.</given-names></name>,
<name><surname>You</surname><given-names>T.</given-names></name>,
<name><surname>Liu</surname><given-names>X.</given-names></name>,
<name><surname>Yang</surname><given-names>X.</given-names></name>,
<name><surname>Bai</surname><given-names>F.</given-names></name>,
<name><surname>Liu</surname><given-names>H.</given-names></name>,
<name><surname>Liu</surname><given-names>X.</given-names></name>,
<name><surname>Guddat</surname><given-names>L. W.</given-names></name>,
<name><surname>Xu</surname><given-names>W.</given-names></name>,
<name><surname>Xiao</surname><given-names>G.</given-names></name>,
<name><surname>Qin</surname><given-names>C.</given-names></name>,
<name><surname>Shi</surname><given-names>Z.</given-names></name>,
<name><surname>Jiang</surname><given-names>H.</given-names></name>,
<name><surname>Rao</surname><given-names>Z.</given-names></name>, and
<name><surname>Yang</surname><given-names>H.</given-names></name></person-group>
(<year>2020</year>) <article-title>Structure of M<sup>pro</sup> from COVID-19 virus and
discovery of its inhibitors</article-title>. <source>Nature</source>, <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Yan</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Cao</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>T.</given-names></name>; <name><surname>Sun</surname><given-names>Q.</given-names></name>; <name><surname>Ming</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Ge</surname><given-names>J.</given-names></name>; <name><surname>Zheng</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>C.</given-names></name>; <name><surname>Hu</surname><given-names>T.</given-names></name>; <name><surname>Hua</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Guddat</surname><given-names>L. W.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Lou</surname><given-names>Z.</given-names></name>; <name><surname>Rao</surname><given-names>Z.</given-names></name> (<year>2020</year>) <article-title>Structure of the RNA-dependent RNA polymerase from COVID-19
virus</article-title>. <source>Science</source>
<elocation-id>eabb7498</elocation-id><pub-id pub-id-type="doi">10.1126/science.abb7498</pub-id>.<pub-id pub-id-type="pmid">32277040</pub-id></mixed-citation></ref></ref-list></back></article>